Full-Time
Senior Director
Global Development Technology Solutions
Updated on 8/1/2026
BeOne
1,001-5,000 employees
Global oncology therapeutics discovery, development, manufacturing
Compensation Overview
$207.8k - $277.8k/yr
Remote in USA
Remote
Some travel is expected as part of assigned duties.
 Business & Strategy (1) |
|---|
Get referred to BeOne
See people who can refer or advise you
- 12+ years of professional experience in data, digital, and information technology with direct oversight and experience in or for the Clinical Development-related area in the pharmaceutical, biotechnology, and/or medical device industries.
- 7+ years of proven leadership experience at a senior level, directing a team of multi-skilled direct reports and associate-level team members.
- 7+ years of combined experience in the design, deployment, and support of Clinical Development-focused digital transformation of processes, platforms, systems, software, and repositories.
- Strong experience in machine learning, artificial intelligence, and generative artificial intelligence methods and technologies to support the Clinical Development function.
- Business relationship management acumen and demonstrable success as a change agent leading or contributing to significant transformational initiatives in organizations.
- Strong experience with software lifecycle methodologies, 21 CFR Part 11 compliance, GxP computer systems validation, and ICH guidelines.
- Accomplished in building and developing people and teams, with comfort working with a broad cross-section of people in direct and matrixed relationships.
- Proficient in project management disciplines including Agile, Scrum, Kanban, and Lean.
- A bachelor's degree or higher is required.
- Collaborate with Clinical Development functions, including Clinical Operations, Safety, Regulatory, Clinical Development, and Pharmacology, to understand scientific strategy, priorities, and unmet digital and technology needs.
- Define and own a multi-year digital and technology roadmap for the Clinical Development organization within R&D, focused on externally or vendor-developed solutions and systems.
- Translate complex scientific and technical needs into clear, documented, and prioritized data, digital, and technology requirements and use cases.
- Oversee the end-to-end process from identification, assessment, onboarding, development or deployment, and launch of technology systems and solutions specific to Development functions.
- Advise Development function and sub-function teams on machine learning, artificial intelligence, and generative artificial intelligence-related requests and needs for externally developed systems.
- Lead end-to-end process assessments to identify, design, and implement automation, optimization, embedded machine learning, artificial intelligence, and generative artificial intelligence technology components and digital tools.
- Oversee enforcement of rigorous data formatting, semantic consistency, and interoperability standards for data ingested from external vendor systems.
- Partner with internal Data Management teams to align vendor system outputs with enterprise-wide master data management strategies and core reference models.
- Oversee data governance guardrails for third-party platforms, ensuring adherence to data security, lineage tracing, and compliance mandates.
- Lead change management programs for externally developed systems and platforms.
- Manage the behavioral shift required for digital adoption and change management initiatives.
- Scan the external landscape for novel digital and technology products, platforms, and systems.
- Provide digital and technology subject-matter expertise for the identification, evaluation, and management of technology vendors.
- Lead, mentor, and manage a high-performing GRDTS team dedicated to the Development function.
- Foster a culture of innovation and accountability and drive professional development.
- Ensure Development-related systems and platforms adhere to relevant pharmaceutical industry regulations and internal security policies.
- Liaise with vendors, Enterprise IT partners, audit, and compliance to coordinate system implementation and change activities.
- Ensure the team is trained in and embeds computer systems validation, compliance, and health authority requirements into operational activities.
- Manage the Development function's technology portfolio budget to maximize return on investment.
- Act as the voice of the Development function within the broader Global Technology Solutions organization, ensuring its needs are prioritized.
- Collaborate with other teams on standards and best practices.
- Engage with peers to define, sponsor, and execute continuous improvements.
BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Dongcheng District, China
Founded
2010
Get referred to BeOne
See people who can refer or advise you
Simplify's Take
What believers are saying
- BRUKINSA and sonrotoclax can expand fixed-duration CLL treatment standards.
- BGB-43395 and BG-C9074 deepen breast-cancer pipeline optionality.
- Q1 2026 revenue reached $1.5 billion, supporting broader R&D investment.
What critics are saying
- Revenue still depends heavily on BRUKINSA, exposing the company to concentration risk.
- Solid-tumor programs remain early-stage, with limited efficacy and tolerability data.
- Insider stock sales can pressure sentiment despite the 10b5-1 plan.
What makes BeOne unique
- Global oncology platform spans hematology, immunology, and solid tumors.
- BRUKINSA anchors a leading hematology franchise across multiple approved markets.
- Large global trial network enables faster, more cost-efficient clinical development.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Retirement Plan
Wellness Program
Paid Vacation
Growth & Insights and Company News
6 month growth
↓ -7%1 year growth
↓ -9%2 year growth
↓ -3%Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.
BeOne Medicines reported $1.5 billion in revenue for the quarter ended December 2025, a 32.8% year-over-year increase, beating the Zacks Consensus Estimate by 3.19%. The company posted earnings per share of $0.58, compared to a loss of $1.43 in the prior year, though this fell short of the $1.60 consensus estimate. Net product revenues reached $1.48 billion, exceeding the $1.45 billion analyst estimate. BRUKINSA generated $1.15 billion, surpassing the $1.09 billion estimate, whilst TEVIMBRA contributed $182 million, slightly below the $191.33 million forecast. The stock has returned 0.6% over the past month, matching the S&P 500's performance. BeOne currently holds a Zacks Rank of 2, indicating potential outperformance.
BeOne Medicines reported fourth quarter 2025 product revenues of $1.5 billion and full-year revenues of $5.3 billion, representing growth of 32% and 40% year-over-year respectively. Product revenue accounted for 99% of total revenue. BRUKINSA, the company's BTK inhibitor, achieved global sales of $1.1 billion in Q4 and $3.9 billion for the full year, up 38% and 49% respectively. US sales reached $845 million in Q4 and $2.8 billion annually. TEVIMBRA generated $182 million in Q4 and $737 million for the year. The company reported GAAP net income of $67 million in Q4 and $287 million for the full year, compared to losses in prior-year periods. Free cash flow reached $942 million for 2025, up $1.6 billion year-over-year. BeOne provided 2026 guidance of $6.2–6.4 billion in total revenue and $1.4–1.5 billion in non-GAAP operating income.
BeOne Medicines is trading at $340.38, representing a 9.44% year-to-date gain and 51.29% total shareholder return over the past year, though recent performance has been mixed with a one-day decline and flat weekly performance. The company appears undervalued against an estimated fair value of $401.52, based on strong revenue growth fundamentals. BeOne reported 41% year-over-year revenue growth in Q2 and raised full-year guidance to $5–5.3 billion, driven by demand for its oncology therapy BRUKINSA. The valuation narrative assumes continued aggressive expansion and rising profitability, supported by an ageing population and increased global healthcare spending. However, risks include potential competition affecting BRUKINSA revenues and possible delays in late-stage trials or regulatory approvals.
BeOne Medicines ( ($ONC) ) has shared an announcement. On November 13, 2025, BeOne Medicines Ltd. entered into a Facilities Agreement with HSBC and other financial ...